ClinicalTrials.gg
TerminatedNCT03307512Updated Sep 13, 2019

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

A Phase 2 interventional study of inhaled human insulin and Insulin Lispro (Humalog U-100) in Safety and Tolerability, sponsored by Dance Biopharm Inc.. Terminated at 1 site in United States. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-13.

Sponsored by Dance Biopharm Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Termination due to incomplete enrollment; planned data analysis not performed

From the registry’s dates

  • Primary completion was Jul 2019, 7 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
925th of 1,353
40 · median 100
Started
2018
with 67 others
Phase 2
292 of 1,695
22 open now
Registered
1,186th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 925th largest by enrollment of the 1,353 interventional ones that give a count, is one of 68 that started in 2018, is one of 292 in phase 2, and was the 1,186th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This will be a randomized, open-label, active-controlled, single dose crossover study with either three or four treatment periods. Investigational treatment is with Dance 501 Human Insulin Inhalation Solution (Dance 501) and the comparator is Insulin Lispro (Humalog®).

Target population will be Non-Diabetic individuals with mild to moderate asthma or chronic obstructive pulmonary disease (COPD) and non-diabetic individuals without underlying lung disease (healthy subjects).

Read the detailed description

The PK and PD profile of Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be compared to subcutaneous injection of insulin lispro.

03

Conditions studied

  • Safety and Tolerability

Keywords

  • inhaled insulin
  • asthma
  • COPD
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • non-diabetic subjects with asthma, or . Non-smokers or smokers quit at least 6 months prior to enrollment. \<= 35 kg/m2. Fasting blood glucose \<= 125 mg/dL.

Exclusion criteria

Exclusion Criteria:

  • pulmonary disorder other than asthma or . Upper respiratory within previous 4 weeks. Significant exacerbation of asthma or COPD symptoms. Hospitalization for asthma or COPD within previous 3 months. medical condition. Current medications interfering with glucose metabolism.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Dance 501

    Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation

    Drug: inhaled human insulin

  • Active comparator
    Insulin Lispro

    Insulin Lispro (Humalog®) will be administered by subcutaneous injection

    Drug: Insulin Lispro (Humalog U-100)

Interventions

  • Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation

    Also known as: Dance 501

  • Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection

    Also known as: Lispro

06

What researchers measure

Primary outcomes

  1. Area under the insulin curve (AUC)

    Area under the insulin curve (AUC)

    Time frame: 10 hours

  2. Area under the glucose infusion rate curve (GIR)

    Area under the glucose infusion rate curve (GIR)

    Time frame: 10 hours

Secondary outcomes

  1. Area under the insulin curve following inhalation of salbutamol

    Area under the insulin curve following inhalation of salbutamol in subjects with asthma

    Time frame: 10 hours

07

Study locations

1 site
  • WCCT
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jul 2019, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 11, 2017
StartActual
Feb 6, 2018
Primary completionActual
Jul 30, 2019
CompletionActual
Aug 30, 2019
Last update
Sep 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03307512
Lead sponsor
Dance Biopharm Inc.
Collaborators
WCCT Global
Responsible party
Sponsor
First posted
Oct 11, 2017
Start date
Feb 6, 2018
Primary completion
Jul 30, 2019
Completion
Aug 30, 2019
Last update
Sep 13, 2019

Study contacts

Timothy S Bailey, MD
principal investigator · AMCR

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion